FDA Approves Minocycline Topical Foam for Rosacea

May 29, 2020


Currently, the use of minocycline is limited orally due to some systemic side effects.

FDA Accepts New Drug Application for Rosacea Treatment Topical Foam

October 17, 2019


The FDA set a 2020 PDUFA action date for FMX103, a topical foam to treat papulopustular rosacea.

Hemali Gunt, PhD: Adjunctive Skin Care for Rosacea

March 02, 2019


Compared to standard cleansers and moisturizers, natural versions for sensitive skin provided benefits to patients with rosacea who were also taking prescription treatments.

Simon Murray, MD: AAD 2019 Sessions to Attend

March 02, 2019


An internist’s perspective on which sessions to attend, from melanoma to inflammatory diseases to cosmetic procedures.

Dermatologists' Antibiotic Prescribing Habits Have Shifted

January 18, 2019


Overall antibiotic prescriptions have dropped, but short-term postoperative prescriptions have increased in recent years.

People with Rosacea Have Higher Odds of Alzheimer's Disease

April 28, 2016


Rosacea patients are at a higher risk of developing Alzheimer’s disease and dementia, according to new research.

Odds of Parkinson's Disease Higher for Rosacea Patients

March 22, 2016


Chronic inflammatory skin condition, rosacea, may be linked to Parkinson’s disease through shared pathogenic mechanisms.

Rosacea Remission Extended with Ivermectin 1% Cream

March 14, 2016


Initial treatment with once-daily ivermectin 1% cream (Soolantra/Galderma) resulted in longer remission for patients suffering from moderate-to-severe papulopustular rosacea, compared to the initial treatment with twice daily metronidazole 0.75% cream.

Research Reveals Relationship Between Rosacea and Glioma Risk

January 29, 2016


Rosacea has been linked to a significantly increased risk of developing glioma.

FDA Approves New Rosacea Foam Treatment

July 31, 2015


The US Food and Drug Administration (FDA) today approved azelaic acid (Finacea Foam/Bayer) 15% for the treatment of inflammatory papules and pustules of mild-to-moderate rosacea.